Vanguard Portfolio Management
NMRA icon

Vanguard Portfolio Management’s Neumora Therapeutics NMRA Stock Holding History

Vanguard Portfolio Management’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.52M Buy
894,791
+709,955
+384% +$1.35M ﹤0.01% 2833
2026
Q1 		$360K Buy
+184,836
New +$479K ﹤0.01% 2989

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Portfolio Management's NMRA Position: Q2 2026 in Review

Vanguard Portfolio Management increased its Neumora Therapeutics (NMRA) stake by 384% in Q2 2026, buying an estimated $1.35M and bringing the position to 894,791 shares worth $1.52M. The position accounts for ﹤0.01% of the portfolio, ranked #2833.

Vanguard Portfolio Management first reported a position in NMRA in Q1 2026 and has held it in 2 quarters since. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • Vanguard Portfolio Management held 894,791 shares of Neumora Therapeutics worth $1.52M as of Q2 2026.
  • Vanguard Portfolio Management bought 709,955 Neumora Therapeutics shares in Q2 2026, an estimated $1.35M.
  • Neumora Therapeutics made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #2833 holding.
  • Vanguard Portfolio Management first reported a position in Neumora Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.